Biologic drug survival rates in the era of anti‐interleukin‐17 antibodies: a time‐period‐adjusted registry analysis

BACKGROUND: Drug survival rates reflect efficacy and safety and may be influenced by the availability of alternative treatment options. Little is known about time‐dependent drug survival in psoriasis and the effect of increasing numbers of biologic treatment options. OBJECTIVES: To determine whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Graier, T., Salmhofer, W., Jonak, C., Weger, W., Kölli, C., Gruber, B., Sator, P.G., Prillinger, K., Mlynek, A., Schütz‐Bergmayr, M., Richter, L., Ratzinger, G., Painsi, C., Selhofer, S., Häring, N., Wippel‐Slupetzky, K., Skvara, H., Trattner, H., Tanew, A., Inzinger, M., Tatarski, R., Bangert, C., Ellersdorfer, C., Lichem, R., Gruber‐Wackernagel, A., Hofer, A., Legat, F., Schmiedberger, E., Strohal, R., Lange‐Asschenfeldt, B., Schmuth, M., Vujic, I., Hoetzenecker, W., Trautinger, F., Saxinger, W., Müllegger, R., Quehenberger, F., Wolf, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248155/
https://www.ncbi.nlm.nih.gov/pubmed/33289075
http://dx.doi.org/10.1111/bjd.19701

Ejemplares similares

Ejemplares similares